Loading clinical trials...
Loading clinical trials...
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer: A Phase II, Single-Arm Clinical Study
Conditions
Interventions
sintilimab+IBI310+chemotherapy
Locations
1
China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Start Date
January 10, 2026
Primary Completion Date
June 10, 2028
Completion Date
January 10, 2030
Last Updated
February 13, 2026
NCT06945484
NCT03620669
NCT04027647
NCT05816499
NCT07493980
NCT07150598
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions